Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II study to determine the safety, tolerability and to identify the MTD and
DLT of Plitidepsin in combination with a fixed dose of Cytarabine in patients with
relapsed/refractory leukemia and to determine the response rate of the combination of
Plitidepsin with Cytarabine in patients with relapsed/refractory AML treated at the MTD.